An observational study in Myasthenia Gravis, sponsored by AstraZeneca. Active, not recruiting at 20 sites in China. Open to participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.
Sponsored by AstraZeneca · Observational
This study is a multi-center, prospective cohort study designed to characterize current clinical practice, clinical and patient-reported outcomes (PROs), disease prognosis, treatment patterns and healthcare resource utilization for Chinese patients with myasthenia gravis (MG). This study will enroll patients with MG as diagnosed by physician. Approximately 1,200 MG patients are intended to be recruited from approximately 40 sites across majority of regions in China. The clinical and PROs included MGFA class, MGFA PIS, MG-ADL (Activities of Daily Living), QMG (Quantitative MG score), MG QOL-15R, EQ-5D etc. All MG patients enrolled will be followed up every 6 months until end of 2027.
324 studies on the registry are indexed under Myasthenia Gravis; 146 are open to participants now.
This study's enrollment of 1,199 is above the median of 140 across 104 observational studies indexed under Myasthenia Gravis.
Browse Myasthenia Gravis studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
This study will recruit patients diagnosed with MG by a physician. The diagnosis of MG patients newly diagnosed prior to enrollment should be based on the clinical characteristics of MG and at least one of the following criteria: (a) Positive serology tests for acetylcholine receptor antibody (AChR Ab), muscle-specific kinase antibody (MuSK Ab), or lipoprotein-related protein 4 (LRP4 Ab); (b) Results of electrophysiological studies (repetitive stimulation, single-fiber electromyography, or both) related to synaptic transmission disorder at the neuromuscular junction; (c) Positive pharmacological test results (such as neostigmine methylsulfate test). Previously diagnosed patients must have a documented MG diagnosis accepted by clinical physician.
This study will enroll patients of all ages who are diagnosed with MG of all MGFA classifications by physicians.
Patients must have the following data to be enrolled in this study:
Exclusion Criteria:
Clinical outcome
MGFA classification (e.g I, II, III, IV, V)
Time frame: Every 6 months up to 3 years
Treatment method
Targeted treatment methods (list of methods, including medication, immunoglobulin, plasma exchange, surgery etc. )
Time frame: Every 6 months up to 3 years
Patient-reported outcome
MG-Activities of Daily Living (MG-ADL, aggregated value in a scale, ranged 0- best to 24- worst)
Time frame: Every 6 months up to 3 years
Clinical outcome
MGFA Post-intervention Status (e.g. CSR, PR, MM)
Time frame: Every 6 months up to 3 years
Clinical outcome
Quantitative MG score (QMG, aggregated value in a scale, ranged 0- best to 39-worst)
Time frame: Every 6 months up to 3 years
Clinical outcome
Physician-reported MG crisis
Time frame: Every 6 months up to 3 years
Clinical outcome
Death
Time frame: Every 6 months up to 3 years
Patient-reported outcome
MG-Quality of Life 15-Revised (MG-QoL15-r, aggregated value in a scale for quality of life, ranged 0- best to 60- worst)
Time frame: Every 6 months up to 3 years
Patient-reported outcome
EuroQol-5D (separate value for five dimensions in a scale for quality of life)
Time frame: Every 6 months up to 3 years
Treatment duration
Therapies start and end date
Time frame: Every 6 months up to 3 years
Treatment dose
Dose (e.g. mg)
Time frame: Every 6 months up to 3 years
Treatment frequency
Frequency (e.g. times/day)
Time frame: Every 6 months up to 3 years
Demographic factors
1. Age (years) 2. Gender (male, female) 3. Residence place (rural, urban) 4. Education 5. Household income
Time frame: Baseline
Healthcare resource utilization
MG-related hospitalization (days)
Time frame: Every 6 months up to 3 years
Cormobidity
Comorbidities (list of related diseases, e.g. autoimmune diseases, cardiovascular disease, hypertension, diabetes etc.)
Time frame: Every 6 months up to 3 years
Healthcare resource utilization
MG-related healthcare costs
Time frame: Every 6 months up to 3 years
MG diagnosis history
MG first time diagnosis date
Time frame: Every 6 months up to 3 years
Vital sign - blood pressure
Blood pressure (mmHg)
Time frame: Every 6 months up to 3 years
Laboratory test - blood cell test
Blood cell counts by cell type tests (e.g. counts/L)
Time frame: Every 6 months up to 3 years
Laboratory tests etc.) - MG-related antibodies
MG-related antibodies including AChR, MuSK, LRP4 etc. (positive or negative).
Time frame: Every 6 months up to 3 years
Vital sign - pulse
Pulse (count/minute)
Time frame: Every 6 months up to 3 years
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca